WO2004039842A3 - Humanized tissue factor antibodies - Google Patents

Humanized tissue factor antibodies Download PDF

Info

Publication number
WO2004039842A3
WO2004039842A3 PCT/DK2003/000741 DK0300741W WO2004039842A3 WO 2004039842 A3 WO2004039842 A3 WO 2004039842A3 DK 0300741 W DK0300741 W DK 0300741W WO 2004039842 A3 WO2004039842 A3 WO 2004039842A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitope
protein
human
humanized
amino acid
Prior art date
Application number
PCT/DK2003/000741
Other languages
French (fr)
Other versions
WO2004039842A2 (en
Inventor
Ivan Svendsen
Kristian Kjaergaard
Stefan Zahn
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to AU2003277832A priority Critical patent/AU2003277832A1/en
Publication of WO2004039842A2 publication Critical patent/WO2004039842A2/en
Publication of WO2004039842A3 publication Critical patent/WO2004039842A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/7454—Tissue factor (tissue thromboplastin, Factor III)

Abstract

In one aspect, the invention provides non-immunogenic high affinity humanized antibodies against human TF, which antibodies inhibit the binding of coagulation factor VII/Vila. In another aspect, the invention provides novel and useful methods for selection of therapeutically effective humanized antibodies against human TF. In a further aspect the invention provides an isolated humanized antibody, that immunoreacts with an epitope P present on a protein, wherein the human framework amino acid sequences of said humanized antibody are derived from a human antibody, wherein said human antibody immunoreacts with an epitope H present on said protein, said epitope H comprising an amino acid residue at a particular position of said protein, which amino acid residue at this particular position of said protein is also comprised within the epitope P with which said humanized antibody immunoreacts.
PCT/DK2003/000741 2002-10-31 2003-10-31 Humanized tissue factor antibodies WO2004039842A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003277832A AU2003277832A1 (en) 2002-10-31 2003-10-31 Humanized tissue factor antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201661 2002-10-31
DKPA200201661 2002-10-31

Publications (2)

Publication Number Publication Date
WO2004039842A2 WO2004039842A2 (en) 2004-05-13
WO2004039842A3 true WO2004039842A3 (en) 2004-09-23

Family

ID=32187133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2003/000741 WO2004039842A2 (en) 2002-10-31 2003-10-31 Humanized tissue factor antibodies

Country Status (2)

Country Link
AU (1) AU2003277832A1 (en)
WO (1) WO2004039842A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064870A2 (en) * 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
CA2527621A1 (en) * 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1749536A1 (en) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Activated factor X stimulants as new antihemorrhagic agents for topical use
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
EP2582728B1 (en) 2010-06-15 2017-08-23 Genmab A/S Human antibody drug conjugates against tissue factor
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
CA3083345A1 (en) * 2017-11-27 2019-05-31 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040921A1 (en) * 1995-06-07 1996-12-19 Ortho Farmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
WO1997018838A1 (en) * 1995-11-21 1997-05-29 Athena Neurosciences, Inc. Therapeutic uses of humanized antibodies against alpha-4 integrin
WO1998001757A1 (en) * 1996-07-08 1998-01-15 Cambridge Antibody Technology Limited Labelling and selection of molecules
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
EP1069185A1 (en) * 1998-04-03 2001-01-17 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
WO2001070984A2 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
WO2003029295A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies
WO2003037911A2 (en) * 2001-10-29 2003-05-08 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
WO1996040921A1 (en) * 1995-06-07 1996-12-19 Ortho Farmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
WO1997018838A1 (en) * 1995-11-21 1997-05-29 Athena Neurosciences, Inc. Therapeutic uses of humanized antibodies against alpha-4 integrin
WO1998001757A1 (en) * 1996-07-08 1998-01-15 Cambridge Antibody Technology Limited Labelling and selection of molecules
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
EP1069185A1 (en) * 1998-04-03 2001-01-17 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
WO2001070984A2 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2003029295A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies
WO2003037911A2 (en) * 2001-10-29 2003-05-08 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FRANK KOLBINGER ET AL: "Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies", PROTEIN ENGINEERING, vol. 6, no. 8, 1993, pages 971 - 980, XP002271768 *
LEONARD PRESTA ET AL: "Generation of a Humanized, High Affinity Anti-tissue Factor Antibody for Use as a Novel Antithrombotic Therapeutic", THROMB HAEMOST, vol. 85, 2001, pages 379 - 389, XP002271767 *

Also Published As

Publication number Publication date
WO2004039842A2 (en) 2004-05-13
AU2003277832A8 (en) 2004-05-25
AU2003277832A1 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
WO2006036291A3 (en) Antibodies directed against amyloid-beta peptide and methods using same
EP1693384A3 (en) Functional immunoglobulins against human serum albumin, fragments thereof, library thereof and methods of production thereof
WO2000005249A3 (en) Synthetic peptides and methods of use for autoimmune disease therapies
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
WO2003068924A3 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
NZ593068A (en) IL-18 antibody
WO2002092771A3 (en) Specific binding proteins and uses thereof
WO2005012493A3 (en) Anti-cd19 antibodies
WO2002020569A3 (en) Mammalian genes; related reagents and methods
WO2005063816A3 (en) Monovalent antibody fragments useful as therapeutics
WO2004013180A3 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
IL210454A (en) Antibody against a cytokine zcytor17 ligand
WO2001070984A3 (en) Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2006014498A3 (en) Universal antibody libraries
WO2006017325A3 (en) Aav vector compositions and methods for enhanced expression of immunoglobulins the same
WO2003046204A3 (en) Humanized collagen antibodies and related methods
WO2004013161A3 (en) Peptide aggregates
WO2004022717A3 (en) Minimally immunogenic variants of humanized col-1 antibody against carcinoembryonic antigen
WO2004039842A3 (en) Humanized tissue factor antibodies
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
WO2005030793A3 (en) Antibodies which bind human cxcr3
WO2003079750A3 (en) ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
WO2000053742A3 (en) Polynucleotides and proteins encoded thereby

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP